Tyrosine kinases play a critical role in signal transduction for several cellular functions including modulation of growth factor signaling, proliferation, carcinogenesis and cell differentiation. Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting such enzymes and have been approved and/or are in clinical trials for treating several solid tumors including hepatocellular carcinoma (HCC). Several TKIs including sorafenib and regorafenib have already been approved for first and second line treatment of HCC, respectively. A plethora of novel TKIs such as lenvatinib and cabozantinib are being investigated for their potential use in the therapeutic management of HCC. The availability of newer TKIs will allow physicians to deliver a more personalized to HCC management. In this Velocity Vlog activity filmed in San Francisco during the American Society of Clinical Oncology’s 2018 Gastrointestinal Cancers Symposium, Dr. Richard S. Finn of the UCLA Geffen School of Medicine outlines the epidemiology and current standard of care for the treatment of HCC; describes the role of TKIs in the therapeutic management of this disease; and discusses the latest clinical trial data presented at the meeting.